Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MITO

Stealth BioTherapeutics (MITO) Stock Price, News & Analysis

Stealth BioTherapeutics logo

About Stealth BioTherapeutics Stock (NASDAQ:MITO)

Key Stats

Today's Range
$0.32
$0.32
50-Day Range
$0.31
$0.32
52-Week Range
$0.16
$1.03
Volume
N/A
Average Volume
946,105 shs
Market Capitalization
$23.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Receive MITO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MITO Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Bolt Biotherapeutics Inc
Sonnet BioTherapeutics Holdings Inc.
Iovance Biotherapeutics Inc (IOVA)
See More Headlines

MITO Stock Analysis - Frequently Asked Questions

Stealth BioTherapeutics Corp (NASDAQ:MITO) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01.

Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stealth BioTherapeutics investors own include Tesla (TSLA), TherapeuticsMD (TXMD), NIO (NIO), Plug Power (PLUG), Allena Pharmaceuticals (ALNA), SCYNEXIS (SCYX) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
8/05/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MITO
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Net Income
$-52,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.09 million
Book Value
($0.79) per share

Miscellaneous

Free Float
N/A
Market Cap
$23.54 million
Optionable
Not Optionable
Beta
1.46
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:MITO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners